Loss of sclerostin promotes osteoarthritis in mice via β-catenin-dependent and -independent Wnt pathways

Arthritis Research and Therapy

Volumn 17, Issue 1, 2015, Pages

  Bouaziz, Wafa ^a   Funck Brentano, Thomas ^a   Lin, Hilène ^a   Marty, Caroline ^a   Ea, Hang Korng ^a   Hay, Eric ^a   Cohen Solal, Martine ^a  

^a UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

[No Author keywords available]

Indexed keywords

AGGRECANASE; BETA CATENIN; COLLAGEN TYPE 10; DISINTEGRIN; GLYCOSAMINOGLYCAN; MATRIX METALLOPROTEINASE; MATRIX PROTEIN; METALLOPROTEINASE; PROTEOGLYCAN; SCLEROSTIN; STRESS ACTIVATED PROTEIN KINASE; THROMBOSPONDIN; WNT3A PROTEIN; GLYCOPROTEIN; SOST PROTEIN, MOUSE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BIOACCUMULATION; BONE MASS; CARTILAGE CELL; CELL DIFFERENTIATION; CONTROLLED STUDY; FEMUR CONDYLE; JOINT INSTABILITY; KNEE MENISCUS; KNOCKOUT MOUSE; MALE; MOUSE; NONHUMAN; OSTEOARTHRITIS; OSTEOARTHRITIS SCORE; OSTEOPHYTE; PATHOGENESIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN SECRETION; SCORING SYSTEM; UPREGULATION; WILD TYPE MOUSE; WNT SIGNALING PATHWAY; ANIMAL; ARTICULAR CARTILAGE; C57BL MOUSE; CHONDROCYTE; CYTOLOGY; DRUG EFFECTS; KNEE OSTEOARTHRITIS; METABOLISM; PATHOLOGY; PHYSIOLOGY; POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

ANIMALS; BETA CATENIN; BLOTTING, WESTERN; CARTILAGE, ARTICULAR; CHONDROCYTES; COLLAGEN TYPE X; DISINTEGRINS; GLYCOPROTEINS; JOINT INSTABILITY; MALE; METALLOPROTEASES; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; OSTEOARTHRITIS, KNEE; POLYMERASE CHAIN REACTION; WNT SIGNALING PATHWAY; WNT3A PROTEIN;

EID: 84928817487     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/s13075-015-0540-6     Document Type: Article

References (35)

1. Arden NK, Leyland KM. Osteoarthritis year 2013 in review: clinical. Osteoarthritis Cartilage. 2013;21:1409-13.
2. Racine J, Aaron RK. Pathogenesis and epidemiology of osteoarthritis. R I Med J. 2013;96:19-22.
3. Murray CJ, Vos T, Lozano R, Naghavi M, Flaxman AD, Michaud C, et al. Disability-adjusted life years (DALYs) for 291 diseases and injuries in 21 regions, 1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet. 2010;380:2197-223.
4. Bijlsma JW, Berenbaum F, Lafeber FP. Osteoarthritis: an update with relevance for clinical practice. Lancet. 2011;377:2115-26.
5. Funck-Brentano T, Lin H, Hay E, Ah Kioon MD, Schiltz C, Hannouche D, et al. Targeting bone alleviates osteoarthritis in osteopenic mice and modulates cartilage catabolism. PLoS One. 2012;7:e33543.
6. Suri S, Walsh DA. Osteochondral alterations in osteoarthritis. Bone. 2012;51:204-11.
7. Goldring MB. Articular cartilage degradation in osteoarthritis. HSS J. 2012;8:7-9.
8. van der Kraan PM, van den Berg WB. Chondrocyte hypertrophy and osteoarthritis: role in initiation and progression of cartilage degeneration? Osteoarthritis Cartilage. 2012;20:223-32.
9. Gong Y, Slee RB, Fukai N, Rawadi G, Roman-Roman S, Reginato AM, et al. LDL receptor-related protein 5 (LRP5) affects bone accrual and eye development. Cell. 2001;107:513-23.
10. Boyden LM, Mao J, Belsky J, Mitzner L, Farhi A, Mitnick MA, et al. High bone density due to a mutation in LDL-receptor-related protein 5. N Engl J Med. 2002;346:1513-21.
11. Baron R, Kneissel M. WNT signaling in bone homeostasis and disease: from human mutations to treatments. Nat Med. 2012;19:179-92.
12. Corr M. Wnt-β-catenin signaling in the pathogenesis of osteoarthritis. Nat Clin Pract Rheumatol. 2008;4:550-6.
13. van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M, et al. Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med. 2004;199:805-14.
14. van Bezooijen RL, Bronckers AL, Gortzak RA, Hogendoorn PC, van der Wee-Pals L, Balemans W, et al. Sclerostin in mineralized matrices and van Buchem disease. J Dent Res. 2009;88:569-74.
15. Chan BY, Fuller ES, Russell AK, Smith SM, Smith MM, Jackson MT, et al. Increased chondrocyte sclerostin may protect against cartilage degradation in osteoarthritis. Osteoarthritis Cartilage. 2011;19:874-85.
16. Roudier M, Li X, Niu QT, Pacheco E, Pretorius JK, Graham K, et al. Sclerostin is expressed in articular cartilage but loss or inhibition does not affect cartilage remodeling during aging or following mechanical injury. Arthritis Rheum. 2012;65:721-31.
17. Kadri A, Ea HK, Bazille C, Hannouche D, Liote F, Cohen-Solal ME. Osteoprotegerin inhibits cartilage degradation through an effect on trabecular bone in murine experimental osteoarthritis. Arthritis Rheum. 2008;58:2379-86.
18. Kramer I, Salie R, Susa M, Kneissel M. Studying gene expression in bone by in situ hybridization. Methods Mol Biol. 2012;816:305-20.
19. Glasson SS, Chambers MG, Van Den Berg WB, Little CB. The OARSI histopathology initiative - recommendations for histological assessments of osteoarthritis in the mouse. Osteoarthritis Cartilage. 2010;18 Suppl 3:S17-23.
20. Gosset M, Berenbaum F, Thirion S, Jacques C. Primary culture and phenotyping of murine chondrocytes. Nat Protoc. 2008;3:1253-60.
21. Stone JE, Akhtar N, Botchway S, Pennock CA. Interaction of 1,9-dimethylmethylene blue with glycosaminoglycans. Ann Clin Biochem. 1994;31:147-52.
22. van der Kraan PM, van den Berg WB. Osteophytes: relevance and biology. Osteoarthritis Cartilage. 2007;15:237-44.
23. Chang MK, Kramer I, Keller H, Gooi JH, Collett C, Jenkins D, et al. Reversing LRP5-dependent osteoporosis and SOST deficiency-induced sclerosing bone disorders by altering WNT signaling activity. J Bone Miner Res. 2014;29:29-42.
24. Li X, Ominsky MS, Niu QT, Sun N, Daugherty B, D'Agostin D, et al. Targeted deletion of the sclerostin gene in mice results in increased bone formation and bone strength. J Bone Miner Res. 2008;23:860-9.
25. Funck-Brentano T, Bouaziz W, Marty C, Geoffroy V, Hay E, Cohen-Solal M. Dkk-1-mediated inhibition of Wnt signaling in bone ameliorates osteoarthritis in mice. Arthritis Rheumatol. 2014;66:3028-39.
26. Burr DB, Gallant MA. Bone remodelling in osteoarthritis. Nat Rev Rheumatol. 2012;8:665-73.
27. Yuasa T, Otani T, Koike T, Iwamoto M, Enomoto-Iwamoto M. Wnt/β-catenin signaling stimulates matrix catabolic genes and activity in articular chondrocytes: its possible role in joint degeneration. Lab Invest. 2008;88:264-74.
28. Lories RJ, Corr M, Lane NE. To Wnt or not to Wnt: the bone and joint health dilemma. Nat Rev Rheumatol. 2013;9:328-39.
29. Nalesso G, Sherwood J, Bertrand J, Pap T, Ramachandran M, De Bari C, et al. WNT-3A modulates articular chondrocyte phenotype by activating both canonical and noncanonical pathways. J Cell Biol. 2011;193:551-64.
30. Sheldahl LC, Park M, Malbon CC, Moon RT. Protein kinase C is differentially stimulated by Wnt and Frizzled homologs in a G-protein-dependent manner. Curr Biol. 1999;9:695-8.
31. Ryu JH, Chun JS. Opposing roles of WNT-5A and WNT-11 in interleukin-1β regulation of type II collagen expression in articular chondrocytes. J Biol Chem. 2006;281:22039-47.
32. Brun J, Fromigue O, Dieudonne FX, Marty C, Chen J, Dahan J, et al. The LIM-only protein FHL2 controls mesenchymal cell osteogenic differentiation and bone formation through Wnt5a and Wnt10b. Bone. 2012;53:6-12.
33. Nguyen J, Tang SY, Nguyen D, Alliston T. Load regulates bone formation and sclerostin expression through a TGFβ-dependent mechanism. PLoS One. 2013;8:e53813.
34. Zhu M, Chen M, Zuscik M, Wu Q, Wang YJ, Rosier RN, et al. Inhibition of β-catenin signaling in articular chondrocytes results in articular cartilage destruction. Arthritis Rheum. 2008;58:2053-64.
35. Zhu M, Tang D, Wu Q, Hao S, Chen M, Xie C, et al. Activation of β-catenin signaling in articular chondrocytes leads to osteoarthritis-like phenotype in adult β-catenin conditional activation mice. J Bone Miner Res. 2009;24:12-21.